Acumen Pharmaceuticals (ABOS)

• Market cap: $64.2M
• 1 day: -0.93%
• 5 days: 0.95%
• 1 month: 0.00%
• 3 months: -23.19%
• 6 months: -55.27%
• Year to date: -42.70%
• 1 year: -72.40%
• 5 years: -94.73%
• 10 years: -94.73%
• Sector: Healthcare
• Industry: Biotechnology

About: Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.

Employees: 52

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

22% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 9

0% more funds holding

Funds holding: 79 [Q4 2024] → 79 (+0) [Q1 2025]

3.81% less ownership

Funds ownership: 70.73% [Q4 2024] → 66.92% (-3.81%) [Q1 2025]

33% less call options, than puts

Call options by funds: $45K | Put options by funds: $67K

39% less capital invested

Capital invested by funds: $73.1M [Q4 2024] → $44.8M (-$28.3M) [Q1 2025]

58% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 33

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $4 277% upside
• Avg. target: $7.50 608% upside
• High target: $11 938% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

UBS Colin Bristow	277% upside $4	Buy Maintained	28 Mar 2025
HC Wainwright & Co. Andrew Fein	938% upside $11	Buy Maintained	28 Mar 2025